Brief: Chimeric Therapeutics Seeks Trading Halt
19/10/2023 23:33
Oct 20 (Reuters) - Chimeric Therapeutics Ltd CHM.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON NEW DATA FOR
PHASE 1A
CLTX CAR T BRAIN CANCER CLINICAL TRIAL
Source text for Eikon: ID:nASX7gMM5g
Further company coverage: CHM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial